ALPL and Pseudoxanthoma elasticum: A drug that acts by selectively inhibiting the enzyme TNAP [18,19,20] is in phase I of clinical trials and is beginning phase II; the activity of this enzyme is elevated in PXE patients and may be responsible, at least in part, for the reduced levels of PPi [3,21,22].